TELL ME MORE ABOUT THIS STUDY
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled, parallel group, study to evaluate the efficacy and safety of two doses of an investigational medicine add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis.
Enrolling Adults 40+ Years
Study Location(s): Bowling Green, KY
Chronic obstructive pulmonary disease (COPD) is an ongoing lung condition caused by damage to the lungs. The damage results in swelling and irritation, also called inflammation, inside the airways that limit airflow into and out of the lungs. This limited airflow is known as obstruction. Symptoms include trouble breathing, a daily cough that brings up mucus and a tight, whistling sound in the lungs called wheezing.
COPD is most often caused by long-term exposure to irritating smoke, fumes, dust or chemicals. The most common cause is cigarette smoke.
Emphysema and chronic bronchitis are the two most common types of COPD. These two conditions usually occur together and can vary in severity among people with COPD.
Chronic bronchitis is inflammation of the lining of the tubes that bring air into the lungs. These tubes are called bronchi. The inflammation prevents good airflow into and out of the lungs and makes extra mucus. In emphysema, the small air sacs of the lungs, called alveoli, are damaged. The damaged alveoli can’t pass enough oxygen into the bloodstream.
Although COPD is a condition that can get worse over time, COPD is treatable. With proper management, most people with COPD can control symptoms and improve their quality of life. Proper management also can lower the risk of other conditions linked to COPD, such as heart disease and lung cancer. (Content source: Mayo Clinic)
There is no cost to participate. Volunteers receive free investigational medicine and follow-up care. No insurance needed. Time and travel compensation may be available.